cas 1340301-52-1|| where to buy 1-propylazetidin-3-ol

Nombre del producto:1-propylazetidin-3-ol

IUPAC Name:1-propylazetidin-3-ol

Unidad de embalaje	Stock disponible	Precio($)
CM746619-1g	in stock	ƥǪ
CM746619-5g	in stock	ǪǪǙ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1340301-52-1 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1340301-52-1; Fórmula molecular:C6H13NO; Punto de fusión:-; Código de sonrisas:CCCN1CC(O)C1; Densidad:

: Número de catálogo:CM746619; Peso molecular:115.18; Punto de ebullición:; Nº Mdl:MFCD18308893; Almacenamiento:

: Azetidines; Azetidines are an important class of saturated four-membered nitrogen-containing heterocyclic compounds. The research hotspots related to this structure mainly focus on two aspects: one is the research of pharmaceutical chemistry; the other is related to chiral azetidines, using rigid azetidine compounds as chiral ligands for asymmetric catalytic reactions. Many nitrogen-containing heterocycles play important roles in drug structures, and in many cases small structural changes can improve ligand selectivity and pharmacokinetic properties.; Where to buy Azetidines; Where to buy ADC-Cytotoxins? Chemenu Provide Azetidines with high quality and competitive price. Contact us Now.

: Palazestrant; Olema Oncology is advancing the development of Palazestrant (OP-1250) in metastatic breast cancer in 2024. Palazestrant is an oral complete ER antagonist (CERAN) and selective ER degrader (SERD). It potently binds and completely blocks transcriptional activity of both wild-type and ESR1-mutant ER with favorable tolerability and anti-tumor activity.
Palazestrant is under clinical development both in combination with Novartis' CDK4/6 inhibitor Kisqali (Ribociclib) as a first-line therapy for advanced estrogen receptor-positive, HER2-negative breast cancer, and as a monotherapy compared to standard of care treatment in second- and third-line advanced or metastatic ER-positive, HER2-negative breast cancer.